🇺🇸 PEFICITINIB in United States

24 US adverse-event reports

Marketing authorisation

FDA

  • Status: approved

Safety signals — FAERS

Adverse reaction reports describe suspected side effects. A report does not mean the drug caused the event — co-medications, underlying disease and coincidence all contribute.

Most-reported reactions

  1. Breast Cancer — 3 reports (12.5%)
  2. Colon Cancer — 3 reports (12.5%)
  3. Interstitial Lung Disease — 3 reports (12.5%)
  4. Therapeutic Response Decreased — 3 reports (12.5%)
  5. Drug Ineffective — 2 reports (8.33%)
  6. Infection — 2 reports (8.33%)
  7. Liver Abscess — 2 reports (8.33%)
  8. Off Label Use — 2 reports (8.33%)
  9. Peritoneal Abscess — 2 reports (8.33%)
  10. Pyrexia — 2 reports (8.33%)

Source database →

PEFICITINIB in other countries

Same drug, different regulators. Each page below lists the local marketing authorisation, HTA position, pricing, and adverse-event data.

Frequently asked questions

Is PEFICITINIB approved in United States?

Yes. FDA has authorised it.

Who is the marketing authorisation holder for PEFICITINIB in United States?

Marketing authorisation holder not available in our data.